Furthermore, expanding on CAR-T cell targets, Poseida Therapeutics Inc. is sponsoring two US-based clinical trials making use of PB technology to manufacture B-cell maturation antigen (BCMA)-specific CAR-T cells for patients with relapsed/refractory multiple myeloma (clinicaltrials.gov ID: NCT03288493) and prostate-specific membrane antigen (PSMA)-specific CAR-T cells for patients with metastatic castration-resistant prostate cancer (clinicaltrials.gov ID: NCT04249947). This evidence concerns the gene FOLH1 and plasma cell myeloma.